Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aptorum Group Limited

Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces 1-for-10 Reverse Stock Split
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Announces Publication of a Co-authored Paper on Development and Validation of a Sensitive Liquid Chromatography with Time-Of-Flight Mass Spectrometry Assay for In Vivo Pharmacokinetic Study of Epigallocatechin-gallate octaacetate (Pro-EGCG)
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Received Nasdaq Notification Letter Regarding Bid Price Deficiency
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
From Aptorum Group Limited
Via Business Wire
Tickers APM
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Tickers APM
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
From Aptorum Group Limited
Via Business Wire
Tickers APM
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.